TY - JOUR
T1 - Homologous recombination DNA repair defects in PALB2-associated breast cancers
AU - Li, Anqi
AU - Geyer, Felipe C.
AU - Blecua, Pedro
AU - Lee, Ju Youn
AU - Selenica, Pier
AU - Brown, David N.
AU - Pareja, Fresia
AU - Lee, Simon S. K.
AU - Kumar, Rahul
AU - Rivera, Barbara
AU - Bi, Rui
AU - Piscuoglio, Salvatore
AU - Wen, Hannah Y.
AU - Lozada, John R.
AU - Gularte-Mérida, Rodrigo
AU - Cavallone, Luca
AU - kConFab Investigators
AU - Aghmesheh, Morteza
AU - Amor, David
AU - Andrews, Leslie
AU - Antill, Yoland
AU - Balleine, Rosemary
AU - Beesley, Jonathan
AU - Blackburn, Anneke
AU - Bogwitz, Michael
AU - Brown, Melissa
AU - Burgess, Matthew
AU - Burke, Jo
AU - Butow, Phyllis
AU - Caldon, Liz
AU - Campbell, Ian
AU - Christian, Alice
AU - Clarke, Christine
AU - Cohen, Paul
AU - Crook, Ashley
AU - Cui, James
AU - Cummings, Margaret
AU - Dawson, Sarah-Jane
AU - De Fazio, Anna
AU - Delatycki, Martin
AU - Dobrovic, Alex
AU - Dudding, Tracy
AU - Duijf, Pascal
AU - Edkins, Edward
AU - Edwards, Stacey
AU - Farshid, Gelareh
AU - Fellows, Andrew
AU - Field, Michael
AU - Flanagan, James
AU - Fong, Peter
AU - Forbes, John
AU - Forrest, Laura
AU - Fox, Stephen
AU - French, Juliet
AU - Friedlander, Michael
AU - Ortega, David Gallego
AU - Gattas, Michael
AU - Giles, Graham
AU - Gill, Grantley
AU - Gleeson, Margaret
AU - Greening, Sian
AU - Haan, Eric
AU - Harris, Marion
AU - Hayward, Nick
AU - Hickie, Ian
AU - Hopper, John
AU - Hunt, Clare
AU - James, Paul
AU - Jenkins, Mark
AU - Kefford, Rick
AU - Kentwell, Maira
AU - Kirk, Judy
AU - Kollias, James
AU - Lakhani, Sunil
AU - Lindeman, Geoff
AU - Lipton, Lara
AU - Lobb, Lizz
AU - Lok, Sheau
AU - Macrea, Finlay
AU - Mann, Graham
AU - Marsh, Deb
AU - McLachlan, Sue-Anne
AU - Meiser, Bettina
AU - Milne, Roger
AU - Nightingale, Sophie
AU - O’Connell, Shona
AU - Pachter, Nick
AU - Patterson, Briony
AU - Phillips, Kelly
AU - Saleh, Mona
AU - Salisbury, Elizabeth
AU - Saunders, Christobel
AU - Saunus, Jodi
AU - Scott, Clare
AU - Scott, Rodney
AU - Sexton, Adrienne
AU - Shelling, Andrew
AU - Simpson, Peter
AU - Spigelman, Allan
AU - Spurdle, Mandy
AU - Stone, Jennifer
AU - Taylor, Jessica
AU - Thorne, Heather
AU - Trainer, Alison
AU - Trench, Georgia
AU - Tucker, Kathy
AU - Visvader, Jane
AU - Walker, Logan
AU - Wallis, Mathew
AU - Williams, Rachael
AU - Winship, Ingrid
AU - Wu, Kathy
AU - Young, Mary Anne
AU - Rezoug, Zoulikha
AU - Nguyen-Dumont, Tu
AU - Peterlongo, Paolo
AU - Tondini, Carlo
AU - Terkelsen, Thorkild
AU - Rønlund, Karina
AU - Boonen, Susanne E.
AU - Mannerma, Arto
AU - Winqvist, Robert
AU - Janatova, Marketa
AU - Rajadurai, Pathmanathan
AU - Xia, Bing
AU - Norton, Larry
AU - Robson, Mark E.
AU - Ng, Pei-Sze
AU - Looi, Lai Meng
AU - Southey, Melissa C.
AU - Weigelt, Britta
AU - Soo-Hwang, Teo
AU - Tischkowitz, Marc
AU - Foulkes, William D.
AU - Reis-Filho, Jorge S.
N1 - Copyright the Author(s) 2019. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
In the original version of this paper, the link to the data record in the Data Availability Statement was incorrectly listed as https:// doi.org/10.6084/m9.figshare.8138912.44. The link has been corrected to https://doi.org/10.6084/m9.figshare.8138912. This has been corrected in the HTML and PDF versions of this article.
PY - 2019/11/23
Y1 - 2019/11/23
N2 - Mono-allelic germline pathogenic variants in the Partner And Localizer of BRCA2 (PALB2) gene predispose to a high-risk of breast cancer development, consistent with the role of PALB2 in homologous recombination (HR) DNA repair. Here, we sought to define the repertoire of somatic genetic alterations in PALB2-associated breast cancers (BCs), and whether PALB2-associated BCs display bi-allelic inactivation of PALB2 and/or genomic features of HR-deficiency (HRD). Twenty-four breast cancer patients with pathogenic PALB2 germline mutations were analyzed by whole-exome sequencing (WES, n = 16) or targeted capture massively parallel sequencing (410 cancer genes, n = 8). Somatic genetic alterations, loss of heterozygosity (LOH) of the PALB2 wild-type allele, large-scale state transitions (LSTs) and mutational signatures were defined. PALB2-associated BCs were found to be heterogeneous at the genetic level, with PIK3CA (29%), PALB2 (21%), TP53 (21%), and NOTCH3 (17%) being the genes most frequently affected by somatic mutations. Bi-allelic PALB2 inactivation was found in 16 of the 24 cases (67%), either through LOH (n = 11) or second somatic mutations (n = 5) of the wild-type allele. High LST scores were found in all 12 PALB2-associated BCs with bi-allelic PALB2 inactivation sequenced by WES, of which eight displayed the HRD-related mutational signature 3. In addition, bi-allelic inactivation of PALB2 was significantly associated with high LST scores. Our findings suggest that the identification of bi-allelic PALB2 inactivation in PALB2-associated BCs is required for the personalization of HR-directed therapies, such as platinum salts and/or PARP inhibitors, as the vast majority of PALB2-associated BCs without PALB2 bi-allelic inactivation lack genomic features of HRD.
AB - Mono-allelic germline pathogenic variants in the Partner And Localizer of BRCA2 (PALB2) gene predispose to a high-risk of breast cancer development, consistent with the role of PALB2 in homologous recombination (HR) DNA repair. Here, we sought to define the repertoire of somatic genetic alterations in PALB2-associated breast cancers (BCs), and whether PALB2-associated BCs display bi-allelic inactivation of PALB2 and/or genomic features of HR-deficiency (HRD). Twenty-four breast cancer patients with pathogenic PALB2 germline mutations were analyzed by whole-exome sequencing (WES, n = 16) or targeted capture massively parallel sequencing (410 cancer genes, n = 8). Somatic genetic alterations, loss of heterozygosity (LOH) of the PALB2 wild-type allele, large-scale state transitions (LSTs) and mutational signatures were defined. PALB2-associated BCs were found to be heterogeneous at the genetic level, with PIK3CA (29%), PALB2 (21%), TP53 (21%), and NOTCH3 (17%) being the genes most frequently affected by somatic mutations. Bi-allelic PALB2 inactivation was found in 16 of the 24 cases (67%), either through LOH (n = 11) or second somatic mutations (n = 5) of the wild-type allele. High LST scores were found in all 12 PALB2-associated BCs with bi-allelic PALB2 inactivation sequenced by WES, of which eight displayed the HRD-related mutational signature 3. In addition, bi-allelic inactivation of PALB2 was significantly associated with high LST scores. Our findings suggest that the identification of bi-allelic PALB2 inactivation in PALB2-associated BCs is required for the personalization of HR-directed therapies, such as platinum salts and/or PARP inhibitors, as the vast majority of PALB2-associated BCs without PALB2 bi-allelic inactivation lack genomic features of HRD.
UR - http://www.scopus.com/inward/record.url?scp=85070388252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/record.url?scp=85075213644&partnerID=8YFLogxK
U2 - 10.1038/s41523-019-0115-9
DO - 10.1038/s41523-019-0115-9
M3 - Article
C2 - 31428676
AN - SCOPUS:85070388252
SN - 2374-4677
VL - 5
SP - 1
EP - 14
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 23
ER -